Trial Profile

Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 24 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
Indications Adenocarcinoma; Biliary cancer; Carcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Pancreatic cancer; Renal cancer
Focus Therapeutic Use
Acronyms MRD-GI

Most Recent Events

25 Jan 2025 Study design were presented at the 2025 Gastrointestinal Cancers Symposium.
20 Jan 2024 According to Trial design presented at the 2024 Gastrointestinal Cancers Symposium, Enrollment began in Q1 2023. 4 pts are enrolled in the CRC cohort
20 Jan 2024 Trial design presented at the 2024 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com